{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:17Z","timestamp":1786982177222,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s12012-020-09613-2","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T08:02:41Z","timestamp":1602921761000},"page":"216-223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9146-8765","authenticated-orcid":false,"given":"Ugur Nadir","family":"Karakulak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elifcan","family":"Aladag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedat","family":"Hekimsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Levent","family":"Sahiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ergun Baris","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Necla","family":"Ozer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salih","family":"Aksu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haluk","family":"Demiroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Goker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"Buyukasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Ozcebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilgun","family":"Sayinalp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Celalettin","family":"Haznedaroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,17]]},"reference":[{"issue":"15","key":"9613_CR1","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","volume":"123","author":"NP Shah","year":"2014","unstructured":"Shah, N. P., Guilhot, F., Cortes, J. E., Schiffer, C. A., le Coutre, P., Brummendorf, T. H., et al. (2014). Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: Follow-up of a phase 3 study. Blood, 123(15), 2317\u20132324. https:\/\/doi.org\/10.1182\/blood-2013-10-532341","journal-title":"Blood"},{"key":"9613_CR2","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.2147\/OTT.S170138","volume":"11","author":"M Chaar","year":"2018","unstructured":"Chaar, M., Kamta, J., & Ait-Oudhia, S. (2018). Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities. OncoTargets and Therapy, 11, 6227\u20136237. https:\/\/doi.org\/10.2147\/OTT.S170138","journal-title":"OncoTargets and Therapy"},{"issue":"8","key":"9613_CR3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkela","year":"2006","unstructured":"Kerkela, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., et al. (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine, 12(8), 908\u2013916. https:\/\/doi.org\/10.1038\/nm1446","journal-title":"Nature Medicine"},{"issue":"7","key":"9613_CR4","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/02841860903229124","volume":"48","author":"GS Orphanos","year":"2009","unstructured":"Orphanos, G. S., Ioannidis, G. N., & Ardavanis, A. G. (2009). Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncologica, 48(7), 964\u2013970. https:\/\/doi.org\/10.1080\/02841860903229124","journal-title":"Acta Oncologica"},{"issue":"24","key":"9613_CR5","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio, G., Kim, D. W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., et al. (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 362(24), 2251\u20132259. https:\/\/doi.org\/10.1056\/NEJMoa0912614","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"9613_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12012-018-9453-3","volume":"18","author":"ARG Francisco","year":"2018","unstructured":"Francisco, A. R. G., Alves, D., David, C., Guerra, L., Pinto, F. J., & Almeida, A. G. (2018). Cardiotoxicity in hematological diseases: Are the tyrosine kinase inhibitors imatinib and nilotinib safe? Cardiovascular Toxicology, 18(5), 431\u2013435. https:\/\/doi.org\/10.1007\/s12012-018-9453-3","journal-title":"Cardiovascular Toxicology"},{"issue":"20","key":"9613_CR7","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boque, C., et al. (2016). Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. Journal of Clinical Oncology, 34(20), 2333\u20132340. https:\/\/doi.org\/10.1200\/JCO.2015.64.8899","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"9613_CR8","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/cncr.24927","volume":"116","author":"FM Johnson","year":"2010","unstructured":"Johnson, F. M., Agrawal, S., Burris, H., Rosen, L., Dhillon, N., Hong, D., et al. (2010). Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer, 116(6), 1582\u20131591. https:\/\/doi.org\/10.1002\/cncr.24927","journal-title":"Cancer"},{"issue":"4","key":"9613_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11936-017-0524-8","volume":"19","author":"R Damrongwatanasuk","year":"2017","unstructured":"Damrongwatanasuk, R., & Fradley, M. G. (2017). Cardiovascular complications of targeted therapies for chronic myeloid leukemia. Current Treatment Options in Cardiovascular Medicine, 19(4), 24. https:\/\/doi.org\/10.1007\/s11936-017-0524-8","journal-title":"Current Treatment Options in Cardiovascular Medicine"},{"issue":"6","key":"9613_CR10","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/echo.14373","volume":"36","author":"S Fang","year":"2019","unstructured":"Fang, S., Zhang, Z., Wang, Y., Jiang, F., Yang, K., He, F., et al. (2019). Predictive value of left ventricular myocardial strain by four-dimensional speckle tracking echocardiography combined with red cell distribution width in heart failure with preserved ejection fraction. Echocardiography, 36(6), 1074\u20131083. https:\/\/doi.org\/10.1111\/echo.14373","journal-title":"Echocardiography"},{"issue":"10","key":"9613_CR11","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/echo.12916","volume":"32","author":"K Orta Kilickesmez","year":"2015","unstructured":"Orta Kilickesmez, K., Baydar, O., Bostan, C., Coskun, U., & Kucukoglu, S. (2015). Four-dimensional speckle tracking echocardiography in patients with hypertrophic cardiomyopathy. Echocardiography, 32(10), 1547\u20131553. https:\/\/doi.org\/10.1111\/echo.12916","journal-title":"Echocardiography"},{"issue":"12","key":"9613_CR12","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"RM Lang","year":"2005","unstructured":"Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., et al. (2005). Recommendations for chamber quantification: A report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Journal of the American Society of Echocardiography, 18(12), 1440\u20131463. https:\/\/doi.org\/10.1016\/j.echo.2005.10.005","journal-title":"Journal of the American Society of Echocardiography"},{"issue":"1","key":"9613_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.21037\/cdt.2017.06.01","volume":"8","author":"D Muraru","year":"2018","unstructured":"Muraru, D., Niero, A., Rodriguez-Zanella, H., Cherata, D., & Badano, L. (2018). Three-dimensional speckle-tracking echocardiography: Benefits and limitations of integrating myocardial mechanics with three-dimensional imaging. Cardiovascular Diagnosis and Therapy, 8(1), 101\u2013117. https:\/\/doi.org\/10.21037\/cdt.2017.06.01","journal-title":"Cardiovascular Diagnosis and Therapy"},{"issue":"1","key":"9613_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjci\/jer316","volume":"13","author":"RM Lang","year":"2012","unstructured":"Lang, R. M., Badano, L. P., Tsang, W., Adams, D. H., Agricola, E., Buck, T., et al. (2012). EAE\/ASE recommendations for image acquisition and display using three-dimensional echocardiography. European Heart Journal - Cardiovascular Imaging, 13(1), 1\u201346. https:\/\/doi.org\/10.1093\/ehjci\/jer316","journal-title":"European Heart Journal - Cardiovascular Imaging"},{"issue":"3","key":"9613_CR15","first-page":"235","volume":"55","author":"C Mornos","year":"2014","unstructured":"Mornos, C., Manolis, A. J., Cozma, D., Kouremenos, N., Zacharopoulou, I., & Ionac, A. (2014). The value of left ventricular global longitudinal strain assessed by three-dimensional strain imaging in the early detection of anthracyclinemediated cardiotoxicity. Hellenic Journal of Cardiology, 55(3), 235\u2013244.","journal-title":"Hellenic Journal of Cardiology"},{"issue":"4","key":"9613_CR16","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1177\/147323000903700406","volume":"37","author":"M Sayitoglu","year":"2009","unstructured":"Sayitoglu, M., Haznedaroglu, I. C., Hatirnaz, O., Erbilgin, Y., Aksu, S., Koca, E., et al. (2009). Effects of imatinib mesylate on renin-angiotensin system (RAS) activity during the clinical course of chronic myeloid leukaemia. Journal of International Medical Research, 37(4), 1018\u20131028. https:\/\/doi.org\/10.1177\/147323000903700406","journal-title":"Journal of International Medical Research"},{"issue":"3","key":"9613_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/hon.967","volume":"29","author":"MS Marcolino","year":"2011","unstructured":"Marcolino, M. S., Boersma, E., Clementino, N. C., Nunes Mdo, C., Barbosa, M. M., Silva, M. H., et al. (2011). The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients. Hematological Oncology, 29(3), 124\u2013130. https:\/\/doi.org\/10.1002\/hon.967","journal-title":"Hematological Oncology"},{"issue":"1","key":"9613_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3906\/sag-1810-81","volume":"49","author":"E Aladag","year":"2019","unstructured":"Aladag, E., & Haznedaroglu, I. C. (2019). Current perspectives for the treatment of chronic myeloid leukemia. Turkish Journal of Medical Sciences, 49(1), 1\u201310. https:\/\/doi.org\/10.3906\/sag-1810-81","journal-title":"Turkish Journal of Medical Sciences"},{"issue":"3","key":"9613_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s12012-016-9386-7","volume":"17","author":"BB Hasinoff","year":"2017","unstructured":"Hasinoff, B. B., Patel, D., & Wu, X. (2017). The myocyte-damaging effects of the BCR-ABL1-targeted tyrosine kinase inhibitors increase with potency and decrease with specificity. Cardiovascular Toxicology, 17(3), 297\u2013306. https:\/\/doi.org\/10.1007\/s12012-016-9386-7","journal-title":"Cardiovascular Toxicology"},{"issue":"1","key":"9613_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","volume":"118","author":"MH Chen","year":"2008","unstructured":"Chen, M. H., Kerkela, R., & Force, T. (2008). Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation, 118(1), 84\u201395. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.776831","journal-title":"Circulation"},{"issue":"35","key":"9613_CR21","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi, J. J., & Deininger, M. (2015). Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. Journal of Clinical Oncology, 33(35), 4210\u20134218. https:\/\/doi.org\/10.1200\/JCO.2015.62.4718","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"9613_CR22","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus, A., O\u2019Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., et al. (2009). Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 23(6), 1054\u20131061. https:\/\/doi.org\/10.1038\/leu.2009.38","journal-title":"Leukemia"},{"issue":"5","key":"9613_CR23","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus, A., Saglio, G., Hughes, T. P., Larson, R. A., Kim, D. W., Issaragrisil, S., et al. (2016). Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia, 30(5), 1044\u20131054. https:\/\/doi.org\/10.1038\/leu.2016.5","journal-title":"Leukemia"},{"key":"9613_CR24","doi-asserted-by":"publisher","DOI":"10.1159\/000505486","author":"G Novo","year":"2020","unstructured":"Novo, G., Di Lisi, D., Bronte, E., Macaione, F., Accurso, V., Badalamenti, G., et al. (2020). Cardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors: A real-world single-center experience. Oncology. https:\/\/doi.org\/10.1159\/000505486","journal-title":"Oncology"},{"issue":"4","key":"9613_CR25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jcmg.2010.12.007","volume":"4","author":"Y Seo","year":"2011","unstructured":"Seo, Y., Ishizu, T., Enomoto, Y., Sugimori, H., & Aonuma, K. (2011). Endocardial surface area tracking for assessment of regional LV wall deformation with 3D speckle tracking imaging. JACC Cardiovascular Imaging, 4(4), 358\u2013365. https:\/\/doi.org\/10.1016\/j.jcmg.2010.12.007","journal-title":"JACC Cardiovascular Imaging"},{"issue":"1","key":"9613_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.echo.2011.10.009","volume":"25","author":"P Reant","year":"2012","unstructured":"Reant, P., Barbot, L., Touche, C., Dijos, M., Arsac, F., Pillois, X., et al. (2012). Evaluation of global left ventricular systolic function using three-dimensional echocardiography speckle-tracking strain parameters. Journal of the American Society of Echocardiography, 25(1), 68\u201379. https:\/\/doi.org\/10.1016\/j.echo.2011.10.009","journal-title":"Journal of the American Society of Echocardiography"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-020-09613-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-020-09613-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-020-09613-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T23:15:26Z","timestamp":1634426126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-020-09613-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,17]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["9613"],"URL":"https:\/\/doi.org\/10.1007\/s12012-020-09613-2","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,17]]},"assertion":[{"value":"2 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}